1 |
Cavallaro U, Christ ofori G. Multitasking in tumor progression: signaling functions of cell adhesion molecules. Ann N Y Acad Sci,2004,1014:58-66.
|
2 |
Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med, 2004,10(2):175-181.
|
3 |
Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med,2004,10(2):182-186.
|
4 |
Ilmonen S, Vaheri A, Asko-Seljavaara S, et al. Ezrin in primary cutaneous melanoma. Mod Pathol, 2005,18(4):503-510
|
5 |
Zhang Y, Hu MY, Wu WZ, et al. The membrane-cytoskeleton organizer ezrin is necessary for hepatocellular carcinoma cell growth and invasiveness. J Cancer Res Clin Oncol, 2006,132(11):685-697.
|
6 |
Chen WL, Yang L, Zeng SG, et al. Effect of using RNA interference to alter iNOS gene expression on the proliferation of tongue squamous cell carcinoma cell line Tca8113. Br J Oral Maxillofac Surg, 2008,46(6):435-438.
|
7 |
Gallo O, Masini E, Morbidelli L, et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst,1998,90(8):587-596.
|
8 |
Thompson L. World Health Organization classification of tumours:pathology and genetics of head and neck tumours. Ear Nose Throat J,2007,85(2):74.
|
9 |
Mathew J, Hines JE, Obafunwa JO, et al. CD44 is expressed in hepatocellular carcinomas showing vascular invasion. J Pathol, 1996,179(1):74-79.
|
10 |
Akisawa N, Nishimori I, Iwamura T, et al. High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun, 1999,258(2):395-400.
|
11 |
Wan X, Mendoza A, Khanna C, et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res, 2005,65(6):2406-2411.
|
12 |
Köbel M, Langhammer T, Hüttelmaier S, et al. Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Mod Pathol, 2006,19(4):581-587.
|
13 |
Valdman A, Fang X, Pang ST, et al. Ezrin expression in prostate cancer and benign prostatic tissue. Eur Urol, 2005,48(5):852-857.
|
14 |
Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med, 2004,10(2):182-186.
|
15 |
王友元, 陈伟良, 杨朝晖, 等. Ezrin 在人涎腺腺样囊性癌中的表达及对ACC-M 细胞增殖、 侵袭活性的影响. 中华口腔医学杂志,2009,44(4):443-446.
|
16 |
卿菁,张诠,赖非云,等. Ezrin 在涎腺腺样囊性癌组织中的表达. 中华肿瘤防治杂志, 2007,14(20):1542-1544.
|
17 |
Rosbe KW, Prazma J, Petrusz P, et al. Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg, 1995,113(5):541-549.
|
18 |
Glynne PA, Darling KE, Picot J, et al. Epithelial inducible nitric-oxide synthase is an apical EBP50-binding protein that directs vectorial nitric oxide output. J Biol Chem, 2002,277(36):33132-33138.
|
19 |
Soliman H, Craig GP, Nagareddy P, et al. Role of inducible nitric oxide synthase in induction of RhoA expression in hearts from diabetic rats. Cardiovasc Res, 2008,79(2):322-330.
|
20 |
Zhang W, Kuncewicz T, Yu ZY, et al. Protein-protein interactions involving inducible nitric oxide synthase. Acta Physiol Scand, 2003,179(2):137-142.
|